Small human study

Retatrutide

Weight and metabolic outcomes as a triple agonist, in earlier-stage human trials than the approved GLP-1 medicines.

A 15-second vertical explainer plays in this frame when the file is published.

What it is

Retatrutide is a triple-agonist peptide studied along GLP-1, GIP, and glucagon pathways. In this library it is rated from earlier-stage human trials, not from the large outcome trials behind approved GLP-1 medicines such as semaglutide and tirzepatide.

Studied for

  • Weight and metabolic outcomes in human trials that are earlier-stage than the approved GLP-1 programmes.
  • Combined GLP-1, GIP, and glucagon receptor activity, as described in that trial literature.

The evidence

Small human study. There is human data, and it is not the same evidence tier as the approved GLP-1 medicines. We are not stating a current approval decision on this page. Earlier-stage means the question is still open in a way the large semaglutide and tirzepatide trials are not.

What this page will not do

  • Do not treat a triple agonist as the equal of an approved GLP-1 medicine because the names sound related.
  • We do not give doses, stacks, or sourcing.
  • A prescribing doctor is who can say what, if anything, is appropriate.

Still open

  • Where the development programme stands, including any approval, which should be checked rather than inferred from this page.
  • How early trial populations compare with the people asking about it.

Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.